IV DMT for Depression: Phase IIa Trial Shows Rapid Results

THE PROTOHUMAN PERSPECTIVE#

Depression isn't a mood problem. I think the word "mood" is doing too much work here — what we're actually talking about is a systemic collapse of motivational architecture, neuroplasticity, and serotonergic signaling that strips people of their capacity to function. And the tools we've had for decades — SSRIs that take weeks to kick in, therapy that requires months of commitment — leave roughly a third of patients with no meaningful relief.

So when a single 10-minute IV infusion of a naturally occurring tryptamine produces antidepressant effects lasting three months in a controlled trial, the implications extend well beyond psychiatry. This is about compressing a therapeutic timeline from months to minutes. For the biohacking and human performance community, short-acting psychedelics represent something genuinely new: a potential intervention that could recalibrate default mode network activity, restore serotonergic tone, and re-open neuroplastic windows — all within a clinical visit shorter than a lunch break. That's not incrementalism. That's a category shift.

THE SCIENCE#

What Is DMT and Why Does Duration Matter?#

N,N-Dimethyltryptamine (DMT) is an endogenous tryptamine — the human body produces it, though in trace amounts — that acts primarily as a serotonin 5-HT2A receptor agonist. It is the same psychoactive compound responsible for the visionary effects of ayahuasca, but when administered intravenously without MAO inhibitors, DMT's psychoactive window compresses dramatically: onset within 1–5 minutes, peak effects lasting roughly 15–30 minutes, full resolution within an hour^[1][5].

This pharmacokinetic profile is what makes DMT categorically different from psilocybin. Psilocybin therapy sessions typically last 6–8 hours and require two trained therapists to be present throughout. The resource burden is substantial, and it limits scalability in public health settings despite psilocybin's proven efficacy^[5]. DMT's short duration could transform psychedelic-assisted therapy from a boutique intervention into something resembling a standard outpatient procedure.

The Erritzoe et al. Trial: Design and Key Findings#

Erritzoe, Barba, Benway and colleagues conducted a phase IIa, double-blind, placebo-controlled, randomized clinical trial evaluating intravenous DMT (SPL026; DMT fumarate) in adults with moderate-to-severe MDD^[1]. The trial was registered at ClinicalTrials.gov (NCT04673383) and published in Nature Medicine in February 2026.

The design was two-stage: Stage 1 was the double-blind, placebo-controlled phase, where participants received either a single 21.5 mg dose of DMT or placebo administered as a 10-minute IV infusion with concurrent psychological support. Stage 2 was a 12-week open-label follow-up.

The results were striking. DMT produced a significantly greater reduction in depression scores at 2 weeks compared with placebo. Improvements appeared as early as the first assessment at 1 week post-dosing — a timeline that makes SSRIs look glacial by comparison. During the open-label phase, antidepressant effects were sustained through 12 weeks^[1][2].

The side effect profile was mild to moderate: infusion site pain, nausea, and transient anxiety were the most commonly reported adverse events. No serious adverse events occurred^[1].

Serotonergic Mechanisms and Neuroplasticity#

This reminds me of something from the neuroplasticity literature — different context, but the pattern holds. DMT's antidepressant action likely involves more than simple 5-HT2A agonism. Preclinical data suggests DMT may promote dendritic spine growth and synaptogenesis via TrkB/BDNF pathways, essentially reopening windows of neural plasticity that depression tends to slam shut^[5]. There's also emerging evidence that psychedelic experiences may downregulate default mode network (DMN) hyperconnectivity — the rumination engine that keeps depressive thought loops cycling.

What does this actually feel like? Participants in psychedelic trials often describe a temporary dissolution of rigid self-referential thinking, followed by a period of cognitive and emotional flexibility. The mystical experience questionnaire (MEQ) scores from these trials consistently correlate with better clinical outcomes, which raises an uncomfortable question for reductionists: is the subjective experience itself therapeutic, or merely an epiphenomenon of the neurochemistry? The honest answer is we don't know yet, and anyone claiming certainty is overstepping the data.

Converging Evidence: The Vaporized DMT Trial#

The Erritzoe trial doesn't exist in isolation. Falchi-Carvalho, Palhano-Fontes and colleagues published an open-label phase 2a trial in Neuropsychopharmacology (April 2025) evaluating vaporized DMT in 14 patients with treatment-resistant depression^[3]. This study used inhaled DMT — a non-invasive delivery route — and reported rapid antidepressant effects.

But here's where it gets complicated. Ramaekers, writing in the same journal, correctly noted that the open-label design of the vaporized DMT trial means the antidepressant effect size may be inflated by expectancy bias^[5]. Patients enrolling in a psychedelic trial likely carry high treatment expectations. The Erritzoe trial's placebo-controlled design addresses this limitation directly, which is why it represents a meaningful step forward in the evidence hierarchy.

I'm less convinced by the open-label data on its own. But taken together — a controlled IV trial showing sustained effects, plus an open-label inhaled trial showing rapid response in treatment-resistant patients — the signal is becoming harder to dismiss.

The 5-MeO-DMT Microdosing Data#

A separate thread worth noting: Bistue Millón, Noguera, Bruno and colleagues published a Phase I trial in Neuropsychopharmacology (July 2025) evaluating sublingual microdoses of 5-MeO-DMT (a structurally related but pharmacologically distinct compound) in adults with moderate depression and anxiety symptoms^[4]. Doses of 6 mg, 9 mg, or 12 mg were given weekly for four weeks. The compound was well tolerated with no significant adverse events, and participants maintained normal daily functioning.

This is a fundamentally different approach — sub-psychedelic dosing without the full visionary experience — and the results are too preliminary to draw clinical conclusions. But it suggests the pharmacological space around short-acting tryptamines is being explored from multiple angles simultaneously.

COMPARISON TABLE#

THE PROTOCOL#

Important caveat: IV DMT for depression is an investigational treatment. It is not approved for clinical use, and no one should attempt to self-administer DMT based on trial data. The following protocol reflects what was used in the Erritzoe et al. trial and is presented for informational purposes.

Step 1: Patient Selection and Screening Candidates were adults with moderate-to-severe MDD. Thorough psychiatric screening is essential — psychedelic interventions carry risks for individuals with personal or family histories of psychotic disorders. Baseline depression severity was assessed using validated instruments.

Step 2: Preparation Sessions Before the dosing day, participants engaged in preparatory psychological sessions. These were relational and time-limited, designed to build therapeutic alliance and set intentions. This isn't just administrative box-checking — the quality of the preparatory relationship appears to matter for outcomes.

Step 3: The Dosing Session A single 21.5 mg dose of DMT fumarate (SPL026) was administered as a 10-minute intravenous infusion. A trained therapist remained present throughout the experience, which typically lasted 15–30 minutes in total. Vital signs were monitored. The setting was calm, controlled, and designed to minimize anxiety.

Step 4: Integration Support Following the acute experience, participants received integration psychotherapy — structured sessions to process and make meaning of the experience. Based on current evidence, this integration component may be critical to sustaining the antidepressant response beyond the acute pharmacological window.

Step 5: Follow-Up Monitoring Depression scores were assessed at 1 week, 2 weeks, and throughout a 12-week open-label follow-up. Any protocol based on psychedelic intervention should include structured follow-up — both for safety monitoring and to track whether therapeutic gains persist or fade.

VERDICT#

Score: 7.5/10

This is a well-designed proof-of-concept trial in a top-tier journal, and the results are genuinely encouraging. A single dose producing antidepressant effects sustained for three months, with good tolerability, is a meaningful signal. The placebo-controlled design elevates it above previous open-label DMT work.

But let me push back on the enthusiasm slightly. The sample was small — this is a phase IIa trial, not a definitive answer. We don't know how this compares head-to-head against SSRIs or psilocybin. We don't know optimal dosing. We don't know who this works best for or whether the mystical experience component is necessary. The involvement of Cybin (the drug developer) in the trial warrants noting — it doesn't invalidate the findings, but it's a conflict of interest that demands replication by independent groups.

The trajectory is promising. The evidence is early. Both things are true simultaneously.